Analyzing biomarkers and risk factors for Alzheimer's disease
Official title: Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic Interactions
Funded at University of Pennsylvania · NIH-10878686 · Data updated 2026-11-12
This study is looking at blood tests to help doctors better diagnose and treat Alzheimer's disease, making sure that people from different backgrounds are included so that everyone can benefit from new treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $369,938 |
| NIH project number | 5U19AG079774-02 |
| Project ID | NIH-10878686 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals from diverse ethnic backgrounds who are at risk for Alzheimer's disease or have early symptoms of cognitive decline.
✕Less likely to help
Patients with advanced Alzheimer's disease or those who do not have any risk factors for the disease may not benefit from this research.
What this research studies
This research focuses on improving the diagnosis and treatment of Alzheimer's disease (AD) by analyzing blood biomarkers that reflect AD pathology. The project aims to ensure that diverse populations are included in clinical trials, which is crucial for developing effective treatments. By studying plasma proteins associated with AD, the research seeks to establish reliable diagnostic thresholds that can be applied across different ethnic groups. This approach also considers non-genetic risk factors that may contribute to AD, enhancing our understanding of the disease's prevention and treatment.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of Alzheimer's disease, ultimately improving treatment outcomes for patients.
How similar studies have gone: Previous studies have shown promise in using blood biomarkers for Alzheimer's diagnosis, but this research aims to expand those findings to include diverse populations, making it a novel approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Yokoyama, Jennifer S — University of Pennsylvania
- Study coordinator: Yokoyama, Jennifer S
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
ALS risk factors in a long-term ALS study
A long-term ALS study is looking at which factors may influence disease risk and progression in people living with ALS.
-
Understanding how work exposures and genes influence ALS risk
A study is building a long-term group of people at higher risk for ALS to see how their jobs, exposures at work, and genes together affect if and when the disease might develop.
-
P-CARRS-BRAIN: Predicting Alzheimer’s risk in South Asians in India using genetic, behavior, and vascular data
Aims to predict Alzheimer’s disease risk in middle-aged South Asians by combining genetic, lifestyle, and vascular information to catch early changes before dementia develops.
-
P-CARRS-BRAIN: Predicting Alzheimer’s risk in South Asians in India using genetics, behavior, and vascular data
Aimed at people 21 and older, this project looks at how biology, behavior, and blood vessel health together may signal the early risk of Alzheimer’s disease and related dementias in South Asians.
-
Understanding how risk factors affect progression of cirrhosis and response to statins in patients with cirrhosis
This project follows people with cirrhosis to see what factors speed up their liver disease and whether statin medicines help prevent worsening.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.